Clinical trials: Upper Extremity Impairments
Hemiparesis
Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke
Of the 5.7 million stroke survivors in the United States, up to 80% exhibit significant weakness in one arm (called "hemiparesis"). This devastating impairment undermines performance of valued activities and quality of life.
- Trial name
- NCT01654315
- Testing
- Myomo Robotic Arm, RTP Standard Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Ohio State University
Diabetes Mellitus, Type 2, Renal Insufficiency
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.
- Trial name
- NCT01064414
- Testing
- Canagliflozin
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
TBI, Attention Deficits
Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors
The overall goal of the proposed project is to perform a preliminary study to assess the potential effects of galvanic vestibular stimulation (GVS) on the outcomes of a cognitive test of attention and the outcomes of…
- Conditions
- TBI, Attention Deficits, Motor Impairments
- Trial name
- NCT01749800
- Testing
- GVS, Armeo Spring
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Spaulding Rehabilitation Hospital
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex
Effect of Cenicriviroc on HIV Neurocognitive Impairment
The study hypothesis is that cenicriviroc will improve cognition in HIV infected individuals with cognitive impairment. The investigators will study the effect of cenicriviroc on cognition in 24 subjects over a 24 week period.
- Conditions
- AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
- Trial name
- NCT02128828
- Testing
- cenicriviroc
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Hawaii
Renal Insufficiency
Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.
- Trial name
- NCT01316055
- Testing
- Dalfampridine-ER
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Stroke, Hemiplegia
Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke
This pilot study will examine a combination therapy for adults with chronic, severe motor impairment of an arm after stroke. The intervention will combine brain stimulation with physical rehabilitation of the arm on the side of…
- Conditions
- Stroke, Hemiplegia, Hemiparesis
- Trial name
- NCT03538795
- Testing
- iTBS&eCIMT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Stroke
Can rTMS Enhance Somatosensory Recovery After Stroke?
Stroke affects over 795,000 Americans every year and has an enormous impact on the well-being of American Veterans with 6,000 new stroke admissions every year.
- Trial name
- NCT02811913
- Testing
- repetitive transcranial magnetic stimulation (rTMS), peripheral sensory stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VA Office of Research and Development